Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
AnnaMed is a multi-faceted company that specializes in both dental services and pharmaceutical development. On the dental side, it offers a range of services including orthodontics, implants, prosthetics, and endodontics, catering to various patient needs in oral health. In addition to its dental practice, AnnaMed is also engaged in the development of Annamycin, a clinical-stage pharmaceutical aimed at treating acute myeloid leukemia. This drug seeks to provide relief for patients suffering from acute cancer, helping them recover and alleviate the pain associated with this serious condition. Through its dual focus on dental care and innovative cancer treatment, AnnaMed addresses critical health challenges faced by patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.